Retatrutide vs Tirzepatide
A side-by-side research reference for Retatrutide and Tirzepatide — mechanism of action, catalogue data, and the key studies behind each compound.
| Comparison | ||
|---|---|---|
| Compound class | Peptides · Injectable vial | Peptides · Injectable vial |
| Mechanism of action | Triple GLP-1 / GIP / glucagon receptor agonist. Adds glucagon-receptor-driven hepatic fat oxidation and thermogenesis to the incretin effects of GLP-1 and GIP. | Dual GLP-1 and GIP receptor agonist ("twincretin"). Activates both incretin receptors simultaneously — GIP amplifies insulin secretion and adipocyte lipolysis while GLP-1 modulates appetite and gastric emptying. |
| Reference concentration | 30mg | 30mg |
| Research form | Injectable vial | Injectable vial |
Key studies on Retatrutide
Key studies on Tirzepatide
Tirzepatide versus Semaglutide for Type 2 Diabetes Management (NEJM SURPASS Study)Tirzepatide dual GLP-1/GIP agonist for chronic weight management (SURMOUNT-1 Trial)Tirzepatide demonstrates superior weight loss compared to semaglutide monotherapyGLP-1/GIP receptor dual agonism: mechanism and metabolic benefits of tirzepatide
More comparisons
Research Use Only
All compounds referenced on this page are sold for in vitro laboratory research use only. Not for human consumption, medical use, or self-administration. Not evaluated by the FDA. This page is for research and informational purposes only.

